Transplanting cryopreserved ovarian tissue in cancer survivors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the presence of tumor-specific markers in ovarian tissue from patients who have survived sarcomas and hematological malignancies. It involves identifying these markers through advanced histological, immunohistochemical, and molecular analyses of patients' diagnostic materials. The goal is to enhance the safety of ovarian tissue transplantation by ensuring that malignant cells are not present in the cryopreserved tissue. This could ultimately help restore fertility in patients who have undergone cancer treatment.

Why it matters

Who can join: the full rules

Inclusion Criteria:

For all groups:

* Patients with Ewing (ES) and synovial (SS) sarcoma, acute lymphoblastic leukemia (LLA), acute myeloid leukemia (LMA), chronic myeloid leukemia (LMC) and myelodysplasia (MDS)
* No objection to the procedure of sampling for cryopreservation or reimplantation of ovarian tissue by the patient's reference oncologist (according to PA105)
* Obtaining informed consent.

Group 1:

* Age \>18 and under 38 at the time of cryopreservation
* Request for cryopreservation of ovarian tissue at the Laboratory Cryopreservation Ovarian Tissue and Cell Cultures/Criobank IRCCS AOUBO

Group 2:

* Age \>18 years
* Ovarian tissue already collected and cryopreserved at the Laboratory for Cryopreservation of Ovarian Tissue and Cell Cultures/Criobank IRCCS AOUBO

Group 3

* Age \> 18 years
* Request for reimplantation of cryopreserved ovarian tissue at the Laboratory for Cryopreservation of Ovarian Tissue and Cell Cultures/Criobank IRCCS AOUBO
* Early menopause or menstrual irregularities

Exclusion Criteria:

Group 1 and 3

* Contraindications to laparoscopy
* HIV, hepatitis B and C, treponema pallidum and positive PAP tests
* Malignant disease involving the ovary or samples to be reimplanted

Group 2 None.

Where it's running

• IRCCS Azienda Ospedaliero-Universitaria di Bologna
  Bologna, Italy Recruiting

Study contacts

• Principal investigator: Renato Seracchioli, MD — IRCCS Azienda Ospedaliero-Universitaria di Bologna
• Study coordinator: Renato Seracchioli, MD
• Email: renato.seracchioli@aosp.bo.it
• Phone: +390512143944

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Testing ZL-6201 for safety and early activity in sarcoma and other solid tumors

  This trial will see if the antibody-drug conjugate ZL-6201 is safe and shows early anti-cancer activity in adults with sarcoma or certain other advanced solid tumors.

  Recruiting at 8 sites Phase 1 Zai Lab (Hong Kong), Ltd. · Los Angeles, California and 7 other locations · NCT07374848

• Intrathecal dexmedetomidine plus fentanyl with bupivacaine for spinal anesthesia during above-knee amputation

  This trial will test whether adding intrathecal dexmedetomidine to fentanyl and bupivacaine gives better and longer pain relief after above-knee amputation for adults with lower-limb sarcoma.

  Recruiting National Cancer Institute, Egypt · Cairo · NCT07276867

• Does platelet storage time affect protection from bleeding in blood cancer patients?

  This project tests whether how long donated platelets are stored (about 5 days versus longer) changes bleeding risk for people with blood cancers and very low platelet counts.

  Recruiting Centre Hospitalier Universitaire de Besancon · Besançon · NCT06805097

• Decentralized care pathway for cancer patients receiving oral treatment

  This study is testing a new way for cancer patients on oral chemotherapy to receive care at home from a nurse instead of going to the hospital, to see if it makes them happier and helps them stick to their treatment.

  Recruiting Institut Claudius Regaud · Toulouse · NCT06797037

• Using cabozantinib with ifosfamide to treat Ewing's sarcoma and osteosarcoma

  This study is testing if a new combination of cabozantinib and high-dose ifosfamide can help children and young adults with Ewing's sarcoma and osteosarcoma that hasn't responded to previous treatments.

  Recruiting at 4 sites Phase 1 Children's Hospital of Philadelphia · San Francisco, California and 3 other locations · NCT06156410

• TLN-499 plus venetoclax in relapsed or refractory solid tumors

  Doctors are testing whether TLN-499 added to venetoclax can help patients with relapsed or refractory solid tumors, including SCLC and certain neuroendocrine cancers.

  Recruiting Phase 1 Treeline Biosciences, Inc. · Camperdown, New South Wales and 2 other locations · NCT07713732

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.